The initial identification of MAGEA3 as a tumor neoantigen in melanoma and non-small cell lung cancer (NSCLC) has prompted many MAGEA3-based cancer vaccines and adoptive T cell therapy studies[34,35]. This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.